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Disorders (or differences) of sex development (DSD) are congenital conditions characterized by
atypical development of genetic, gonadal or phenotypic sex. This terminology recognizes the simple
but fundamental biology of the nature of sex chromosome (XY or XX) organizing the development of
the gonads (testis or ovary) whose hormones (effectively androgens in fetal life) then determine the
typical genital phenotype (male or female) and likely cause an imprinting of the fetal brain [1].
DSDs include a wide spectrum of conditions mostly due to genetic variants, altered hormonal
secretion or abnormal peripheral sensitivity to gonadal hormones, that are all able to change the typical
male or female fetal development. The impact of DSD on the quality of life of affected persons and
their families is remarkable, as most DSD conditions involve complex clinical, endocrinological and
psychological challenges. Expert opinion and shared decision are required, e.g., for sex assignment at
birth (and eventually re-assignment later on), evaluation about gonadal surgery, because of the risk
of gonadal neoplasia, hormone replacement therapy from adolescence onward, fertility counselling,
and holistic long-term monitoring and preventive care of health. Thus, optimal management of
individuals with DSD requires expert knowledge in this very specialized area, which is available in
interdisciplinary DSD teams working at centers of excellence for DSD care [2,3].
In the last two decades, impressive improvements in both clinical as well as research approaches
have been reached, allowing better understanding of genetic and physio-pathologic basis of old and new
DSDs. National as well as international networks have been established and an international registry,
namely the I-DSD (https://home.i-dsd.org/) has been recognized as common database, increasing the
number of DSD individuals contributing with their data towards better knowledge on DSDs and their
long-term outcome. The future challenge for health professionals will lie in integrating specific basic
information with comprehensively defined clinical and endocrine phenotypes as well as long-term
consequences. Such advances will permit to optimize the care of patients and the counselling for
parents. Concerning the perspective of societies on DSDs, several countries and cultures significantly
enhanced their sensitivity on the topic and changed their opinion/attitude to accept and include persons
with a DSD and expand the strict binary male and female sex/gender categories with either a third,
atypical or gender-neutral category [2,4].
This themed issue on DSD of the International Journal of Molecular Sciences presents a series of
articles written by colleagues who have been recognized as true experts in each chosen area of DSD.
They cover several hot topics, provide some state of the art papers on specific areas and update some
research or management aspects.
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Ali et al. [5] summarize the long experience of the International Disorders of Sex Development
(I-DSD) and International Congenital Adrenal Hyperplasia (I-CAH) registries. They demonstrate that
the registries are indispensable tools for monitoring clinical and patient-centered outcomes. The authors
also demonstrate that registries allow to gather large enough cohorts in DSDs by strict collaborative
efforts to perform meaningful research on rare conditions.
Neirijnck and co-workers [6] address a poorly explored issue that is the roles of insulin/IGF system
in sexual development and reproduction of both males and females. They highlight some interesting
new findings and unanswered questions that remain open for additional studies.
On the basis of their long-lasting clinical and laboratory experience, Baronio et al. [7] update
genetic, biochemical, and clinical features of 46, XX DSD due to androgen excess in monogenic disorders
of steroidogenesis. They elaborate on the precise role of steroidogenic enzymes and cofactors, stressing
that understanding steroidogenesis is a key factor for the comprehension of DSDs and other processes
related to human reproduction and fertility.
The risk of gonadal germ cell cancer (GGCC) is increased in some patients with DSD [2]. Looijenga
and colleagues [8] discuss the possibility to stratify individuals with an increased tumor risk with
parameters other than histological investigation of a gonadal biopsy. They summarize current
opportunities as well as limitations in predicting the personal risk of GGCC in a single specific
individual with DSD.
Rodríguez Gutiérrez et al. [9] explore the revolutionary techniques of cellular reprogramming
and guided in vitro differentiation, permitting to exploit the versatility of induced pluripotent stem
cells to create alternative models for DSD, ideally on a patient-specific personalized basis.
Grinspon and Rey [10] provide insight into the molecular explanation of XX maleness.
It frequently occurs in XX individuals in the presence of a translocated SRY on a X chromosome
or autosome. However, new genomic technologies allow the discovery of novel mechanisms
explaining the development of testicular tissue in the absence of SRY expression in the embryonic
undifferentiated gonads.
Camats et al. [11] explain that the broad phenotypes of individuals with DSD may be due to
oligogenic inheritance instead of single gene defect. Based on their own research in carriers of NR5A1
variants and of MAMLD1 variants, they demonstrate that multiple genetic hits may contribute to
a specific DSD phenotype, unique to each individual. This also suggest that multiple genes work
together in a concerted network for typical sex development.
Tyutyusheva and colleagues [12] report on the molecular basis of complete androgen insensitivity
syndrome and discuss some practical topics including management of the gonads, hormonal
replacement therapy during adolescence and adulthood, bone health, and metabolism.
Ristori et al. [13] raise a very hot topic. They report on the impact of sex hormones and genetic
background on brain sexual differentiation and gender identity, concluding that the sexual dimorphic
brain could be the anatomical substrate of dimorphic psychosexual development, on which gonadal
hormones may have a shaping role during prenatal and pubertal periods.
The authors contributing to this Special Issue of the Journal have been selected based on their
high-quality expertise and their abilities to make complex topics available to all health care providers.
We hope that the readers will find this themed issue not only enjoyable but also helpful for the care of
individuals with DSD.
We would like to take the opportunity to express our gratitude and thanks to all the authors
involved in this selected issue for their high-level papers. We also thank the reviewers for their time
and expertise, as well as the Chief Editors of the International Journal of Molecular Sciences for giving
us the honor of publishing this special issue.
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